Popular Articles
Grapefruit Benefits

New Jersey Senator Proposes Plan To Avert HIV/AIDS Drug Copayments
New Jersey state Sen. Joseph Vitale (D) -- chair of the Senate Health, Human Services and Senior Citizens Committee -- earlier this week proposed a plan to temporarily reduce rebate checks to senior citizens earning $100,000 to $150,000 in an effort to alleviate the effects of possible budget cuts on certain populations, the Newark Star-Ledger reports. Vitale"s proposal also would avert planned $6 to $15 prescription drug copayments for people living with HIV/AIDS in the state (Livio, Newark Star-Ledger, 5/12). The copayments are part of Gov. Jon Corzine"s (D) $29.8 billion spending proposal for the state"s new fiscal year and would collect $1.36 million by creating copayments for HIV/AIDS drugs based on a sliding scale determined by income. The copayments would affect 9,000 people living with HIV/AIDS who have obtained no-cost medicine from the state because they do not qualify for other assistance programs. Advocates said that the copayments will hurt patients who are already struggling because of the poor economy (Kaiser Daily HIV/AIDS Report, 4/23). According to the Star-Ledger, Vitale"s proposal would save the state $15.7 million, including $9.7 million needed to allow 17,000 low-income families to enroll in the state"s health insurance program, FamilyCare. Senate Budget Committee Chair Barbara Buono (D) said that she does not believe it is possible to restore program cuts "given the collapse of revenues." According to the Office of Legislative Services, the current deficit for this year"s budget, which ends June 30, is at least $1.2 billon. Vitale said, "Our convictions are going to be tested as we come to terms with the fact that we simply don"t have enough money to fund all of the state"s priorities." He added, "But unless funding is restored for programs like NJ FamilyCare, Medicaid drug benefits and the AIDS Drug Distribution Program, I will be voting against the" fiscal year 2010 budget (Newark Star-Ledger, 5/12).
generic viagra online
Innovative Treatment Approach Offers New Hope For Eczema Sufferers With Moderate To Severe Disease PROTOPIC Ointment Can Help Prevent Eczema Flares
Today sees the European launch of the first topical calcineurin inhibitor to be approved for the maintenance treatment of eczema to prevent flares and prolong flare-free intervals. PROTOPIC ointment (tacrolimus monohydrate) is already licensed to treat moderate and severe eczema (atopic dermatitis), often involving the treatment of flares as and when they occur.* It is now also approved for twice-weekly application to previously affected skin to prevent these exacerbations and prolong flare-free periods in PROTOPIC-responsive patients.ò€  Clinical studies have shown that this new approach brings significant benefits with over 40% of patients with moderate to severe eczema remaining flare-free for at least a year.1 Flares are known to place an enormous burden on patients. The International Study of Life with Atopic Eczema (ISOLATE) found that about 55% of these patients worried about the onset of their next exacerbation and that they spent on average over a third of the year (136 days) with their eczema in flare.2
News of the day
A Feasible, Simple And Convenient Model For Study Of Rectal Carcinoma
The method of building a rabbit rectal VX2 carcinoma model by injecting the cell suspension of VX2 cells into the wall of the rectum guided by X-ray fluoroscopy is feasible. The advantages of the model are ease of establishment, short growth period, and high stability. The rectal VX2 carcinoma established in this rabbit model is similar to human rectal carcinoma in aspects of pathological representation, tumor development, and metastasis. It offers an ideal major animal model for the study of rectal carcinoma, and especially profits the study of the staging of rectal carcinoma in imaging.
Endocrinology

Medicare Fraud Taints California Device Maker And New Jersey Clinic

A California device maker settles a Medicare fraud case while a New Jersey doctor and his office manager are accused in a Medicare fraud scheme. The Wall Street Journal / Dow Jones reports: "Endoscopic Technologies Inc., a privately held medical-device manufacturer, will pay $1.4 million to settle Medicare fraud claims related to surgical ablation devices used in heart surgery, the U.S. Department of Justice said Tuesday. U.S. officials alleged the San Ramon, Calif., company paid kickbacks to health-care providers that used its ablation devices and advised them on how to seek inflated Medicare payments for procedures using the devices. In addition, the Justice Department said the company, known as Estech, promoted surgeries using ablation devices when less-invasive procedures would have been appropriate and that it marketed the devices to treat abnormal heart rhythm, a use unapproved by the U.S. Food and Drug Administration" (Burns, 7/14). The Oakland Tribune reports on the same case: "The government said these actions violated the Food, Drug and Cosmetic Act and led to submission of false and fraudulent claims in violation of the False Claims Act. ... The case against Estech was filed in federal court in Texas under the False Claims Act"s "qui tam" provisions, which let private citizens sue on behalf of the United States and receive part of any settlement or judgment. The filer for this case will get $210,000. Similar lawsuits against other surgical ablation device makers are still pending in Texas" (Richman, 7/14). In a separate case, The Star-Ledger reports on a New Jersey doctor accused of fraud at the Center for Lymphatic Disorders in Egg Harbor Township: "An Atlantic County surgeon and his office manager have been charged with defrauding Medicaid, Medicare and private insurance companies out of more than $8.5 million, state officials announced yesterday. Khashayar Salartash, 42, of Linwood and his office manager, Farah Iranipour Houtan, 51, of Egg Harbor Township, allegedly conducted the fraud between August 2002 and June 2007 while working at Salartash"s treatment center, The Center for Lymphatic Disorders LLC. State officials said Salartash and Houtan fraudulently received $593,363 from Medicaid, $4.7 million from Medicare and $3.3 million from private carriers after improperly billing for services." The paper notes: "The eight-count indictment, issued Monday by a state grand jury, includes charges of conspiracy, health care claims fraud, Medicaid fraud and misconduct by a corporate official. State officials said the defendants claimed Salartash had personally provided or supervised medical services, when in fact they were separately performed by a therapist or nurse. They also allegedly billed for surgery when only therapy services were provided" (Megerian, 7/15). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):